Phase 3 Clinical Trials With Primary Completion Dates in February 2018

This is a list of Phase 3 trials with primary completion dates in February 2018 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ANTH Anthera Pharmaceuticals, Inc. 2018-02-01 Phase 3 NCT03051490 RESULT: Reliable, Emergent Solution Using Liprotamase Treatment
BHVN Biohaven Pharmaceutical Holding Company Ltd. 2018-02-01 Phase 3 NCT03237845 Safety and Efficacy in Adult Subjects With Acute Migraines
CLSD Clearside Biomedical, Inc. 2018-02-01 Phase 3 NCT03097315 Suprachoroidal Injection of CLS-TA in Subjects Non-infectious Uveitis
CLSD Clearside Biomedical, Inc. 2018-02-01 Phase 3 NCT02595398 Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis
ENDP Endo International plc 2018-02-01 Phase 3 NCT01210352 Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects
GRFS Grifols, S.A. 2018-02-01 Phase 3 NCT02604810 Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
GRFS Grifols, S.A. 2018-02-01 Phase 3 NCT02697292 IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy
KMPH KemPharm, Inc. 2018-02-01 Phase 3 NCT03292952 KP415 Classroom Study in Children (6-12 Years of Age) With ADHD
MESO Mesoblast Limited 2018-02-01 Phase 3 NCT02032004 Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
MESO Mesoblast Limited 2018-02-01 Phase 3 NCT01854567 P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
ONTX Onconova Therapeutics, Inc. 2018-02-01 Phase 3 NCT01928537 Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
ONTX Onconova Therapeutics, Inc. 2018-02-01 Phase 3 NCT01241500 Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
PRAH PRA Health Sciences, Inc. 2018-02-01 Phase 3 NCT02817828 E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - EU/Russia Study